Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Genomic Health and Argonaut Manufacturing Services

NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, Genomic Health reported a $3.2 million realized gain in 2016 from a sale of equity securities in connection with the sale of a portion of its Invitae stock holdings. The company further sold all its remaining shares in Invitae in January 2017 for $10.2 million, resulting in a realized gain of $2.8 million.


Argonaut Manufacturing Services, a contract manufacturing organization for the life science and molecular diagnostics markets, announced that it has received ISO 13485:2016 certification from the British Standards Institute.

The company also said this week that it has received a $5 million credit facility from Pacific Western Bank division Square 1 Bank. Argonaut will use the proceeds to support capital expenditures associated with its recent expansion.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.